The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance

Plain-language summary

This study evaluates the effect of the antibiotic Rifabutin in lung disease caused by Mycobacterium abscessus that shows inducible resistance to clarithromycin. Adults aged 18 and over with laboratory-confirmed M. abscessus lung infection who are suitable for antibiotic treatment may take part. It is being carried out in Phase 4 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 4

Status

Recruiting

Sponsor

National Taiwan University Hospital

Intervention

Rifabutin, No Rifabutin

Start date

1/1/2026

Estimated completion

6/18/2026

Countries

Taiwan

Related genes

Locations

• Douliu, Taiwan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Adults aged ≥ 18 years
* Diagnosis of pulmonary disease caused by Mycobacterium abscessus confirmed by clinical evaluation and laboratory results
* Antimicrobial susceptibility testing indicating inducible resistance to clarithromycin
* Clinically stable and suitable for antibiotic treatment
* Radiographic evidence of active pulmonary infection
* Willing and able to provide informed consent

Exclusion Criteria:

* Known hypersensitivity to rifabutin or intolerance to other study medications
* Pregnant or breastfeeding women